ATH

33.3%

0.4¢ alterity therapeutics limited

Oligomeric and iron were what cought my attention

First 14 Last

Share
Profile

Follow
gumboot

384 Posts.

19

15/07/21

17:14

Post #: 54531817
Share

Originally posted by pivalde: ↑

Stamler was one of the authors of this paper. Now in this news report to shareowners, he has more possibilities to tell proudly what facts in his opinion are the most valuable for the shareowners, in comparison to the critical scientific audience.

-"ATH434 preserves neurons while reducing α-synuclein in areas of pathology is exactly what we were hoping to see".

-"we believe that ATH434 can treat the underlying cause of this devastating disease which has no approved therapy".

- " treatment with ATH434 was neuroprotective and improved motor function, ........as well as animal models of Parkinson’s
Disease".(a reference to earlier Finkelstein paper in Parkinson's disease animal models, PD is the main indication for ATH434 in the future)

- ", ATH434 reduced both the aggregated form of α-synuclein and the so-called toxic oligomeric form, which is thought to underlie the spreading of the disease to other neurons".

-"ATH434 significantly reduced brain iron in areas of pathology, consistent with its mechanism of action". ( most likely there will be a mitochondrion level paper later explaining more exactly the mechanism of action, maybe Stamler already knows this)

- "the first time that ATH434 preserved neurons in a region of the brain called the striatum, that is known to be affected in patients with
MSA". ( Striatum is affected also in PD, not only in MSA, but this is a very important issue, IMO).

- "ATH434 improved performance on diverse motor tests".

Expand

Oligomeric and iron were what cought my attention

ATH Price at posting: 4.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BUX

Buxton projects new graphite province discovery at WA Narryer play

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 3 more messages in this thread...

First 14 Last

Add ATH (ASX) to my watchlist

(20min delay)
Last 0.4¢		Change 0.001(33.3%)		Mkt cap ! $21.28M

Open	High	Low	Value	Volume
0.3¢	0.4¢	0.3¢	$34	10K

Buyers (Bids)

No.	Vol.	Price($)
28	17196248	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	130790145	27

View Market Depth

No.	Vol.	Price($)
28	17196248	0.003
68	89903179	0.002
29	140710133	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	130790145	27
0.005	18848455	22
0.006	22089363	18
0.007	54073650	25
0.008	42418463	31

Last trade - 16.10pm 04/10/2024 (20 minute delay)

ATH (ASX) Chart

Oligomeric and iron were what cought my attention

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Oligomeric and iron were what cought my attention

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News